Product Information
INSULIN ASPART FLEXPEN 100 UNIT/ML PEN is a generic product labeled by Novo Nordisk, priced at $8.9607 per ML under NDC 73070010315. Its NADAC has been published 337 times since Apr 22, 2020.
Strength
100 [iU]/mL
Manufacturer
Novo NordiskNDC
73070010315
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
5/20/2026
Active Ingredients
INSULIN ASPARTApproval Type
Biologic (BLA)
FDA Application
BLA020986On Market Since
1/22/2003
Pharmacological Classes
Price Statistics
The NADAC for INSULIN ASPART FLEXPEN 100 UNIT/ML PEN has been published 337 times since Apr 22, 2020, and over the history we have for it it has declined 49.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9607 per ML |
|---|---|
| All-time high | $18.0493 (Nov 16, 2022) |
| All-time low | $8.9444 (Sep 18, 2024) |
| 52-week high | $8.9645 |
| 52-week low | $8.9540 |
| Median price | $17.8565 |
| Average price | $14.0951 |
| Largest weekly change | -50.0% (Jan 10, 2024) |
| Weeks tracked | 337 |
| Tracking since | Apr 22, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin aspart market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN ASPART FLEXPEN 100 UNIT/ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN ASPART FLEXPEN 100 UNIT/ML PEN, manufactured by Novo Nordisk, is $8.9607 per ML (NDC 73070010315), effective Sep 30, 2026.
How has the price of INSULIN ASPART FLEXPEN 100 UNIT/ML PEN changed over time?
Over the history we have for it, the NADAC for INSULIN ASPART FLEXPEN 100 UNIT/ML PEN has declined 49.9%. It has been tracked across 337 weekly CMS publications since Apr 22, 2020.
What are the highest and lowest recorded NADAC prices for INSULIN ASPART FLEXPEN 100 UNIT/ML PEN?
Since Apr 22, 2020, the NADAC for INSULIN ASPART FLEXPEN 100 UNIT/ML PEN has ranged from a low of $8.9444 (Sep 18, 2024) to a high of $18.0493 (Nov 16, 2022), with a median of $17.8565 per ML.
Are there cheaper alternatives to INSULIN ASPART FLEXPEN 100 UNIT/ML PEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NOVOLOG MIX 70-30 VIAL, is $6.9287 per ML — about 23% below INSULIN ASPART FLEXPEN 100 UNIT/ML PEN.
Who manufactures INSULIN ASPART FLEXPEN 100 UNIT/ML PEN?
INSULIN ASPART FLEXPEN 100 UNIT/ML PEN (NDC 73070010315) is labeled by Novo Nordisk, and CMS classifies it as a generic product.